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Abstract 
 
Glutamate neurotoxicity and pro-inflammatory cytokines have an important role in the central sensitization 
of neuropathic pain. The purpose of the present study was to evaluate anti-hyperalgesic effect of repeated 
administration of ceftriaxone, which selectively activates and increases the expression of glutamate 
transporter, as well as minocycline, a selective inhibitor of microglia activation, either alone or together in 
Wistar rats subjected to the chronic constriction injury (CCI) of sciatic nerve. Ceftriaxone (100, 150 and 200 
mg/kg) and minocycline (25, 50 and 100 mg/kg) were administered intraperitoneally from the day of surgery 
for seven consecutive days. Thermal hyperalgesia was assessed by focal radiant heat source on the hind paw 
of animals one day before surgery and on 3, 5, 7, 10 and 14 days following that. Ceftriaxone dose 
dependently, attenuated thermal hyperalgesia in animals. None of the administered doses of minocycline 
affected the CCI induced-thermal hyperalgesia in neuropathic animals. A fixed dose of minocycline (50 
mg/kg) combined with three different doses of ceftriaxone administered for 7 consecutive days yielded a 
potentiating effect in the enhancing latency time to noxious thermal stimulus remaining until the14th day 
post-surgery. The results suggest that modulation of microglia activity could have a supportive role in the 
improvement of CCI-induced thermal hyperalgesia and combination of such classes of drugs which have no 
antibiotic effects could be a new and promising therapeutic strategy for treatment. 
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INTRODUCTION 
 
Injury to peripheral nerves is one of the 
most common causes of neuropathic pain. This 
kind of chronic pain is characterized by two 
hallmarks of allodynia and hyperalgesia 
subsequent to nerve injury (1,2). Neuropathic 
symptoms poorly respond to current drugs and 
still a large percentage of patients have been 
suffering from pain. Presently available 
therapies are non-steroidal anti-inflammatory 
drugs (NSAIDs), opioids, tricyclic anti-
depressants, anticonvulsants, anti-arrhythmics 
and topical agents. Unfortunately all of these 
treatments are of limited efficacy due to the 
serious adverse effects restricting their 
usefulness (3). Other explanations for low 
satisfactory of patients may be due to 
unresolved exact cellular and molecular 
mechanisms involved as well as interaction of 
complex mechanisms in the induction of this 
kind of pain (4). 
Many studies have demonstrated that 
microglia may have an important role in the 
pathogenesis of neuropathic pain (5,6). The 
neuroprotective role of minocycline, a second-
generation tetracycline with good penetration 
into CNS, has been shown in 
neurodegenerative diseases such as multiple 
sclerosis, Parkinson’s disease, spinal cord 
injury and stroke (7,8). However, there are few 
and inconsistent results on its effects on 
neuropathic pain. 
Mechanical allodynia was attenuated          
by chronic intrathecal administration of 
minocycline in traumatic spinal cord injury in 
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rats (9,10). Another study indicated that 
intraperitoneal (i.p.) administration of 
minocycline attenuates mechanical hyper-
algesia and allodynia (11). Thermal anti-
hyperalgesic effect of minocycline at doses of 
10, 20 and 40 mg/kg in warm water (42 °C) 
was revealed in a study by Zanjani and co-
workers (12).  
It has been reported that repeated i.p. 
administration of minocycline attenuated 
mechanical hyperalgesia in chronic 
constriction injury (CCI) rats (13). In contrast 
with these results, anti-nociceptive effect of 
systemic administration of minocycline was 
not shown by Hua and co-workers (14). 
Tolerance to morphine decreased by 
minocycline and pentoxyfylline in CCI-
exposed mice, while these drugs have no effect 
on mechanical allodynia and thermal (cold 
plate) hyperalgesia, individually (15).  
On the other hand, the role of glutamate, the 
primary excitatory amino acid neuro-
transmitter, has been established in the central 
sensitization of neuropathic pain and the 
development of hyperalgesia. Clearance of 
glutamate in neural synaptic space has been 
done via transporters, among these glutamate 
transporter 1 (GLT1) provides more than                 
90% of the total glutamate uptake which 
mostly occurs in astroglia, other major 
member of glia (16).  
It has been indicated that downregulation of 
GLT1 has a major role in several neuro-
degenerative diseases including neuropathic 
pain (17,18). It has recently been shown that 
the level of GLT1 is increased by β-lactam 
antibiotics (19). Antinociceptive effect of 
ceftriaxone as a member of β-lactam family 
has been recently reported (20). 
We recently reported that co-administration 
of ceftriaxone and minocycline produces more 
anti-allodynic effect than that presented by 
each of the drugs alone (21). Therefore this 
investigation was set to evaluate the effect of 
ceftriaxone and minocycline alone and in 
combination on the CCI-induced thermal 
hyperalgesia (as the other behavioral response 
of neuropathic pain) in rats for assessing 
whether a low subeffective dose of 
minocycline would potentiate the anti-
hyperalgesia effects of ceftriaxone. 
MATERIALS AND METHODS 
 
Animals  
All animal procedures followed the ethical 
guidelines for investigation on experimental 
pain in conscious animals (22). Experiments 
were performed on healthy male Wistar rats 
weighting 220-260 g, maintained on standard 
conditions with free access to rat food and 
water. The experiments were done between 8 
a.m to 13 p.m to prevent fluctuation in 
response. The experimental protocol was 
approved by Isfahan University of Medical 
Sciences and conducted in accordance with the 
internationally accepted principles for 
laboratory animal use and care (22). 
 
Drugs and solutions  
Ceftriaxone (JaberEbneHayyan Pharma-
ceutical Co., Tehran, Iran) was dissolved in 
saline solution (0.9% NaCl) and injected in a 
dosage range of 100, 150 and 200 mg/kg/i.p. 
once daily, from the day of surgery for 7 
continuous days. Minocycline (STADA, 
Arzneimittel, GmbH) was suspended in water 
using tween 80 and injected in a dosage range 
of 25, 50 and 100 mg/kg /i.p. once daily, from 
the day of surgery for 7 continuous days. Test 
doses were chosen with respect to earlier 
studies (15,20). Gabapentin was donated by 
Tehran Darou Pharmaceutical Co. (Tehran, 
Iran), dissolved in saline solution (0.9% NaCl) 
and injected at a dose of 100 mg/kg once daily 
for 7 continuous days. 
 
Chronic constriction injury surgery of sciatic 
nerve  
CCI, a classic model of neuropathic pain, 
originally described by Bennetand Xie, was 
induced in animals (23). Induction of 
anesthesia was performed by a cocktail 
consisting ketamine (64 mg/kg, i.p.) and 
xylazine (1.4 mg/kg, i.p.). After shaving the 
skin, the surgical area was scrubbed by 
povidone iodine solution. A blunt incision was 
made at the mid-thigh level of left hind paw 
through biceps femoris muscle to expose 
common sciatic nerve. The connective tissue 
was freed from nerve. Next, four ligatures by 
4-0 chromic gut suture, proximal to the sciatic 
trifurcation, were loosely placed around the 
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sciatic nerve until a slight twitching was 
observed in the expected hind paw with an 
intervals of 1-1.5 mm among sutures. In sham-
operated rats, the same surgical procedure was 
followed but without any ligature around the 
nerve. Animals were then placed in a              
heated area for surgical recovery and after that 
kept in pairs. 
 
Study Protocol 
Rats were randomly divided into the 
following groups:  
1) Control group: The animals subjected to 
CCI surgery were treated with vehicle. Vehicle 
was 1% tween 80 in saline (v/v) and 
administered at a dose of 1 ml/kg. 
2) Sham groups: The animals without the CCI 
surgery were treated with vehicle and the 
highest dose of ceftriaxone (200 mg/kg) or 
minocycline (100 mg/kg), respectively. 
3) Groups I, II and III: CCI surgery animals 
were treated with three different doses of 
ceftriaxone alone (100, 150 and 200 mg/kg), 
respectively. 
4) Groups IV, V and VI: CCI surgery animals 
were treated with three different doses of 
minocycline alone (25, 50 and 100 mg/kg), 
respectively. 
5) Groups VII, VIII and IX: CCI surgery 
animals were treated with three combinations 
of minocycline (50 mg/kg) and ceftriaxone 
(100, 150 and 200 mg/kg), respectively. 
6) CCI surgery animals were treated with 
gabapentin (100 mg/kg) alone. 
Dosage selection in combination therapies was 
based on the results from single administration 
of drugs. Administration of drugs was begun 
immediately following surgery and continued 
for 7 successive days. All of drugs were 
administered via intraperitoneal route. 
 
Thermal withdrawal threshold 
Thresholds for response to thermal stimulus 
was assessed with a plantar test apparatus 
(model 37370; Ugo Basile Biological 
Instruments, Comerio, Italy), according to 
Hargreaves methods (24). At first the animals 
were placed in the clear Plexiglas chambers of 
the apparatus on the top of a glass floor to 
accommodate to the new environment, for 
about 15 min. When the animals became calm, 
a movable infrared radiant heat source was 
focused behind the paw and activated. The 
time from initial heat source activation until 
paw withdrawal was recorded in seconds. Paw 
withdrawal latency was defined as the amount 
of time it took until hind paw began to shake 
or remove from the surface. The test was 
carried out 3-4 times every 1 min and the 
average was considered as the result of the 
test. A cut-off time of 30 s was chosen to 
prevent tissue injury.  
The test was repeated if the withdrawal of 
the paw was suspected to be as locomotion or 
grooming. The experiments were conducted in 
a randomized and blinded manner by the same 
experimenter. Assessment of thermal 
hyperalgesia performed at different times, 
before (baseline latency) and after surgery 
(i.e., days of 3, 5, 7, 10 and 14 post-CCI). 
Experimenter was blinded with respect to drug 
administration. For comparison of the data, 
they were converted to percent maximum 
possible effect (%MPE) according to the 
following equation: 
%MPE= [(AUC value of treatment) − (AUC value of 
control) /(ceiling AUC value of assay) − (AUC value of 
control)] ×100 (25). 
Statistics 
Time-courses of antinociceptive effects of 
drugs either individually or in combination 
were constructed by plotting the paw 
withdrawal latency as a function of time. A 
two-way analysis of variance (ANOVA) with 
repeated measures followed by Bonferroni’s 
post-hoc analysis was used to examine the 
time-courses of behavioral changes after 
various treatments.  
The overall antinociceptive effects of drugs 
during the 14-day observation period were 
expressed as the area under the curve (AUC) 
calculated by trapezoidal method (26). The 
results then converted to the MPE%. If the 
observed MPE% of combination therapy 
exceeded the theoretical sum of MPE% of 
individual drugs, it was considered as a 
potentiating effect and if they were similar, it 
was considered as additive effect and for the 
case of theoretical sum less than observed 
effect, it was considered as a sub additive 
interaction (26). Data of MPE% were analyzed 
by ANOVA followed by Tukey post-hoc 
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comparison test and presented as mean ± SEM 
for 6-8 rats per group. Statistical significance 
between two groups (the theoretical response 
and the experimentally derived values) was 
evaluated using the Student’s t-test. For 
analysis of data, SPSS software was used. 
Differences at P<0.05 were considered as 
significant. 
 
RESULTS 
 
Anti-hyperalgesia effects of single 
administration of drugs  
When paw withdrawal latency to painful 
(constant intensity) radiant heat stimulus 
decreases, it means that thermal hyperalgesia 
has been developed. After five days of 
operation, vehicle-treated CCI group (control) 
showed significant hyperalgesia to radiant heat 
beam compared to pre-surgery day (day 0). 
This reduction in latency time to heat stimulus 
was from 22.4 ± 1.5 s on day 0 to 12.7 ± 1.5 s 
on day 5 following surgery (P<0.01 by          
paired t-test). On the contrary, sham operated 
group behaved normally and showed no 
significant variation to radiant heat stimulation 
(20.7 ± 1.7 s and 20.6 ± 1.9 s on day 0 and 5, 
respectively) which was stable throughout the 
study. High doses of ceftriaxone and 
minocycline administered to sham animals 
showed no anti-hyperalgesic effect per se (data 
not shown). Thermal hyperalgesia was not 
attenuated in CCI animals receiving three 
different doses of minocycline as compared to 
control group. Ceftriaxone at low doses of 100 
and 150 mg/kg also was not superior to vehicle 
in increasing the latency to thermal stimulus. 
However, latency to thermal stimulus was 
significantly increased by ceftriaxone at the 
dose of 200 mg/kg on days 5, 7, and 10 post-
surgery. Repeated administration of 
gabapentin attenuated thermal hyperalgesia           
in CCI rats, although this improvement             
was reversible and declined following 
discontinuation of treatment. The time course 
of anti-hyperalgesic effects of drugs is 
depicted in Fig. 1 (A and B). 
 
Anti-hyperalgesia effects of drugs in 
simultaneous administration 
No visible adverse effects were observed 
with the doses of ceftriaxone tested in this 
study whereas minocycline treated animals 
with dose of 100 mg/kg daily showed diarrhea 
during the study. Due to ineffectiveness of 
minocycline at any of the administered doses, 
the interaction of both drugs could not be 
evaluated by the isobolographic method. 
Thereby, we selected a fixed dose of 
minocycline (50 mg/kg) with three different 
doses of ceftriaxone.  
The AUC of combination therapies was 
calculated based on the time course of anti-
hyperalgesic activity of drugs in combination 
and then anti-hyperalgesic effect was 
expressed as the percentage of MPE%                
and compared to the theoretical sum of the 
effects when administered individually 
(expected value).  
Comparison of the MPE% on thermal 
hyperalgesia with combination of minocycline 
(50 mg/kg/day), and ceftriaxone 100 mg/kg 
which had no anti-hyperalgesic effect in CCI 
animals, resulted in a significantly higher 
effect than the one corresponding to theoretical 
sum of individual drugs (33 ± 13 vs. 18.5 ± 3, 
P<0.05 by student’st-test; Fig. 2, panel A). 
Giving minocycline (50 mg/kg) to animals 
receiving ceftriaxone 150 mg/kg produced 
even a higher latency time to thermal stimulus 
with a MPE about 39 ± 2. 5 which was 
significantly different from that was expected 
from alone administration of drugs (21 ± 3.1, 
P<0.05 by student’s t-test; Fig. 2, panel B), 
indicating a potentiation of effect.  
When comparing percentages of maximum 
experimental and theoretical effects of 50 
mg/kg minocycline combined with 200 mg/kg 
ceftriaxone for seven days, combination                 
again yielded a potentiating effect                  
(64 ± 12.6 vs. 33 ± 5.1, P<0.01 by student’s t-
test; Fig. 2, panel C).  
Gabapentin exhibited an MPE about 48.2 ± 
10.5. Time course of antihyperalgesic effects 
of the combination treatments revealed that 
antihyperalgesic effect remained even up to 
the 14th day after surgery (seven days after the 
discontinuation of drugs) with ceftriaxone 200 
plus minocycline 50 (P<0.01) as well as 
ceftriaxone 150 plus minocycline 50 (P<0.05), 
but not the low dose of ceftriaxone (100 
mg/kg) + minocycline and reference drug, 
gabapentin (Fig. 1, panel C, D and E). 
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Fig. 1. Time course of the antihyperalgesic effects produced by repeated administration of minocycline (Min 25, 50 and 
100 mg/kg, A) and ceftriaxone (Cef 100,150, and 200 mg/kg, B), as well as the combination of a fixed dose of 
minocycline (50 mg/kg) with three different doses of ceftriaxone (100,150, and 200 mg/kg) in chronic constriction 
injury (CCI)animals (C, D and E, respectively). Administration of drugs was performed once daily from the day of 
surgery, for 7 consecutive days. Dotted horizontal bars indicate the duration of drug administration. Withdrawal 
threshold to radiant heat stimulus was assessed at days 3, 5,7,10, and 14 post-surgery. Data were analyzed by two-way 
analysis of variance (ANOVA) followed by Bonferroni’s post-hoc analysis to examine the time-courses of behavioral 
changes after various treatments. Data were expressed as mean ± SEM for n=6-8/group. *P<0.05, **P<0.01 indicate 
significant difference in comparison to control (CCI-vehicle) group. Gabapentin (Gbp 100 mg/kg) is the reference drug. 
* 
* 
Duration of treatment 
Duration of treatment 
Duration of treatment Duration of treatment 
  Duration of treatment 
------------------------------- 
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Fig. 2. Antihyperalgesia effect produced by repeated i.p. co-administration of minocycline (Min 50 mg/kg) with A; 
ceftriaxone 100 mg/kg (Cef 100), B; ceftriaxone 150 mg/kg (Cef 150) and C; ceftriaxone 200 mg/kg (Cef 200) daily to 
animals subjected to chronic constriction injury(CCI) surgery. Data are expressed as the percentage of maximal possible 
effect (%MPE). Withdrawal threshold was assessed at days 3, 5, 7, 10, and 14 after surgery. Data were analyzed by 
one-way analysis of variance (ANOVA) followed by Tukey post-hoc test. Statistical significance between two groups 
(the theoretical response and the experimentally derived values) was evaluated using the Student’s t-test and expressed 
as mean ± SEM for n=6-8 group.*P<0.05, **P<0.01 comparison is made between observed and expected effects of 
drug combination with paired t test, #P<0.05, ##P<0.01, ###P<0.001 indicate significant change in comparison to 
control (CCI-vehicle) group. 
 
DISCUSSION 
 
Glutamate neurotoxicity and increase in the 
pro-inflammatory cytokines have been 
contributed to the central sensitization of 
neuropathic pain. Minocycline, a second-
generation tetracycline which is a selective 
inhibitor of microglia activation (7,8), and 
ceftriaxone, a member of beta lactam family, 
which is selectively activates and increases      
the expression of GLT1 (19), have been                          
suggested to possess therapeutic potential              
for the treatment of a variety of              
neurological disorders, distinct from their 
antimicrobial properties.  
This study aimed to evaluate anti-
hyperalgesic activity of repeated admin-
istration of minocycline and ceftriaxone 
against painful thermal stimulus alone and in 
combination, in rats underwent to CCI model 
of peripheral neuropathic pain. An advantage 
of CCI is inducing a profound thermal 
hyperalgesia compared to what is seen in other 
kinds of neuropathic pain models (27).  
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Vehicle-treated animals subjected to CCI 
developed hypersensitivity to radiant thermal 
stimulus is in line with previous studies (27). 
We observed that administration of 
ceftriaxone, alone, was effective in reducing 
CCI-induced thermal hyperalgesia only at the 
highest dose (200 mg/kg, i.p.).  
Hu  and colleagues also evaluated thermal 
antihyperalgesic activity of ceftriaxone in CCI 
model of neuropathic pain in Sprague–Dawley 
rats. In Hu and co-workers study, thermal 
hyperalgesia was evoked 3 days post-surgery 
with a mean latency about 14 s before surgery, 
whereas in the present study, it was observed 
on the 5th day after the surgery with a baseline 
threshold about 22 s. The observed 
discrepancies could be due to using different 
animal species, suggesting the importance of 
genetic impact on the hypersensitivity to pain, 
and different applied methods in experiments 
(i.e. different intensity of applied thermal 
stimuli). In contrast, thermal hyperalgesia was 
unaffected by 7-days administration of 
minocycline at any of doses tested for,                   
in our laboratory.  
Our data are in agreement with the results 
obtained by i.p. minocycline on mechanical 
allodynia and cold hyperalgesia in Mika and 
co-workers and Hua co-workers studies 
(14,15) but are in contrast to the results by 
intrathecal administration of minocycline 
(9,28) which suggests the important role of 
administration route. However, minocycline 
crossing from blood brain barrier has 
completely been established (29). Therefore it 
might be hypothesized that i.p. administration 
of minocycline is not able to reach enough 
high concentration in the CNS or after 
systemic administration some interfering 
peripheral or central mechanisms oppose              
the possible spinal anti-nociception effect              
of minocycline. 
Since anti-allodynic effect of minocycline 
has been shown in many studies (12,21), 
another plausible explanation would be 
participation of different mechanisms in the 
induction of thermal hyperalgesia and 
mechanical allodynia/hyperalgesia. It has 
previously been shown that myelinated A 
fibers (Aδ and Aβ) convey mechanical 
noxious and the non-noxious signals along 
with cold noxious signals, while the non-
myelinated C fibers mediate mainly heat 
nociception (30,31).  
Therefore, it might be speculated that 
microglia activation is somewhat different in 
the stated pathways and have more important 
role in the allodynia induced by myelinated A 
fibers rather than to thermal hyperalgesia 
induced by non-myelinated C fibers. The lack 
of efficacy was observed with minocycline in 
our study might be due to different treatment 
procedures as in most of studies, one or two 
preemptive doses of minocycline is 
administered before induction of injury (11). 
In our study however, treatment was started 
following surgery suggesting the limited role 
of microglia after induction of injuries.   
However, analysis of MPE% based on the 
AUC of combination treatments at all of 
applied doses of ceftriaxone showed potentiation 
against thermal hypersensitivity in CCI animals. 
Interestingly more antihyperalgesic effect 
against thermal stimulus was observed with the 
high dose of ceftriaxone plus minocycline 
compared to reference drug gabapentin. 
Although the attenuation of thermal hyperalgesia 
with combination therapies decreased after 
discontinuation of treatment (on the 7th day 
post-surgery) but remained significantly 
different through 14thday after the surgery with 
doses 200 + 50 and 150 + 50 mg/kg of 
ceftriaxone+minocycline respectively, compared 
to ceftriaxone alone. As a result, a sustained 
antinociceptive effect would be hypothesized 
with the combination therapy. 
It should be mentioned that although 
enhanced concentration of glutamate leads to 
excitotoxicity and pathological events; 
however, it is a crucial neurotransmitter in 
CNS which takes part in many physiologic 
processes including excitatory synaptic 
transition (32). 
As a result, complete clearance of 
glutamate might not be a good strategy. 
Furthermore, reversal of microglia activity is 
not a desirable goal because these cells are 
also responsible for producing trophic factors 
and immune surveillance (33,34). Selective 
ablation of microglia led to exacerbation of 
ischemia injury in brain (35). Hence, 
combination therapy with lower doses of 
applied drugs could prevent such undesirable 
Potentiation of anti-hyperalgesic effect of ceftriaxone by minocycline 
41 
adverse effects. Generally, since minocycline 
had no effect on thermal hypersensitivity of its 
own, it seems that spinal neuroimmune 
dysregulation has less powerful effect in the 
development of thermal hyperalgesia. Colburn 
and co-workers. reported less correlation of 
microglia activation compared to astrocytes in 
inducing peripheral neuropathic pain 
behavioral changes (36).  
In summary, the exact mechanisms 
involved in the thermal antihyperalgesic 
effects of minocycline and ceftriaxone in 
combined was not evaluated in our study. 
However, considering the beneficial effects of 
combination pharmacotherapy for neuropathic 
pain and based on our results, it seems that 
application of minocycline together with 
ceftriaxone could have more antinociceptive 
effect. Designing new antibiotic derivatives 
that are devoid of antibacterial activity with 
interfering on the stated pathways would be a 
promising neuroprotective strategy in 
neurodegenerative diseases such as 
neuropathic pain. 
 
CONCLUSION 
 
In summary, the exact mechanisms 
involved in the thermal antihyperalgesic 
effects of combination of minocycline and 
ceftriaxone were not evaluated in our study. 
However, considering the beneficial effects of 
combination pharmacotherapy for neuropathic 
pain and based on our results, it seems that 
application of minocycline together with 
ceftriaxone could have more antinociceptive 
effect. Designing new derivatives of these 
antibiotics that are devoid of antibacterial 
activity with effect on the stated pathways 
would be a promising neuroprotective strategy 
in neurodegenerative diseases such as 
neuropathic pain. 
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